July 15, 2022 7:56am

In these markets, we are always waiting for data from multiple sources

Pre-open indications: 2 Negative Indications, 2 Sell into Strength, 2 Negative Indications and 1 Puff/Pump/Promote

RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

The 8:00 A.M., ET edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are UP +0.43% or (+132 points), S&P futures are UP +0.28% (+10 points) and NASDAQ futures are UP +0.17% (+20 points) early in the pre-open – so far,


U.S. stock futures rose Friday

European markets were higher,

Asia Pacific markets were mixed or struggled for direction.



Stock indexes tumbled on Thursday while “firming the case for the Fed to raise rates.

The Dow shed -0.46%, or 142.62 points, while the S&P 500 dipped -0.3% or -11.40 points while the Nasdaq inched +0.03% 0r +3.60 points higher.

As earnings season heats up, adding to a whirlwind of inflation-recession-Fed uncertainty, volatility for the market rally and individual stocks seems highly likely to continue.

Economic Data Docket: June retail sales, as well as import and export prices at 8:30 a.m. ET. The June industrial production report is expected at 9:15 a.m. ET. Preliminary July data for consumer sentiment is out at 10 a.m. ET.


RegMed Investors’ (RMi) closing bell: “cell and gene therapy sector slumps as markets dump” … https://www.regmedinvestors.com/articles/12517

Ebb and flow –

Q3/22 – 1 holiday, 3 negative and 6 positive closes

Q2/22 –

June – 1 holiday, 9 positive and 11 negative closes

·         May - 11 positive and 10 negative closes

·         April - 1 holiday, 6 positive and 13 negative closes


·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Reverse Indications to Positive:

Alnylam Pharmaceuticals (ALNY) closed down -$4.116 to $138.54 after Wednesday’s -$3.15 with a positive +$1.01 or +0.73% pre-open indication,

BioLife Solutions (BLFS) closed down -$0.20 to $15.59 with a positive +$0.77 or +4.94% pre-open indication,


Negative Indications:

uniQure NV (QURE) closed down -$0.98 to $22.69 <52-week low of $12.52> with a negative -$0.69 or -3.04% pre-open indication,

Vericel (VCEL) closed down -$0.85 to $27.00 <52-week low of $22.42> with a negative -$0.80 or -2.96% pre-open indication,


Sell into Strength:

CRISPR Therapeutics (CRSP) closed up +$1.21 to $81.91 after Wednesday’s +$1.65 after Tuesday’s +$5.34 and Monday’s -$2.99 with a positive +$0.18 or +0.22% pre-open indication,

Beam Therapeutics (BEAM) closed up +$0.53 to $56.12 after Wednesday’s +$2.71, Tuesday’s +$2.43 and Monday’s -$1.56 with a positive +$0.08 or +0.14% pre-open indication,


Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed up +$0.12 to $6.00 <52-week low of $1.21> after Wednesday’s +$1.33 to $5.88 with 376 shares traded <3 mo. Average = 1,721 shares>, Tuesday’s +$0.03 to $4.55 with 175 shares traded, Monday’s -$1.189 with 5,387 shares traded and last Friday’s -$0.55 to $5.70 with 2,334 shares traded.

·         BSTG seems to have the ONLY avenue to finance to utilize non-U.S. Chinese investors?

·         How much lipstick is a lot on this pig with an almost 4-year-old IND and NO clinical trial initiation?

·         WATCH and be ready for a BIG reverse of shares to enable offering from multiple private placements as it tries to facilitate an offering with Newbridge Securities


The BOTTOM LINE: I try to keep it simple … and short!

We are up, down, up and down – it gets tiring! Portfolios are wailing, not crying yet, there is hope for some depressed equities.

Volume was lower on the Nasdaq as the sector followed as well.

The sector is tied to the Nasdaq, “All the key indexes are down sharply for the week, which started with the Nasdaq hitting resistance once again at its 10-week moving average. The indexes are all below their 21-day moving averages. After trending lower for several sessions, perhaps the "uptrend under pressure" is due for a bounce. But it doesn't have to happen anytime soon, and perhaps Thursday's rally off lows was the "bounce." <IBD>

Be prepared, earnings or LPS (loss-per-share) sessions are on their way and many companies will be just as glad to get them out as fast-as-possible to re-set ANY trajectory in August for September.”

There is VALUE out there however, it’s about playing or betting the timing of the sector.

We are left with choosing to hang on to “our” portfolio position as it is a given that the sector shifts from fierce, sudden sell-offs to gaining altitude or ascending not to its value but, better than it was.

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.